TOPIC TAGS for this article:
Pharma + Biotech, Litigation
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY CAMDEN VICINAGE
Click on a topic to display all headlines on that subject
Bond Amount Increased to $62 Million for Potential Recovery by SSJR Client Apotex After Successful Budesonide Trial
15 April 2013
SSJR has secured an additional $2 million bond from AstraZeneca, adding to an existing $60 million bond, to allow recovery of damages and costs sustained by SSJR client Apotex as a result of an injunction improvidently issued by the District Court. If the trial court’s recent decision that the AstraZeneca’s patents are not infringed and invalid is affirmed by the appellate court, Apotex will make a claim for damages and costs to recover the full $62 million in bonds posted by AstraZeneca.